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Abstract
No adeno-associated virus (AAV) capsid has been described in the literature to exhibit a primary 
oligodendrocyte tropism when a constitutive promoter drives gene expression, which is a 
significant barrier for efficient in vivo oligodendrocyte gene transfer. The vast majority of AAV 
vectors, such as AAV1, 2, 5, 6, 8 or 9, exhibit a dominant neuronal tropism in the central nervous 
system. However, a novel AAV capsid (Olig001) generated using capsid shuffling and directed 
evolution was recovered after rat intravenous delivery and subsequent capsid clone rescue, which 
exhibited a > 95% tropism for striatal oligodendrocytes after rat intracranial infusion where a 
constitutive promoter drove gene expression. Olig001 contains a chimeric mixture of AAV1, 2, 6, 
8 and 9, but unlike these parental serotypes after intravenous administration Olig001 has very low 
affinity for peripheral organs, especially the liver. Furthermore, in mixed glial cell cultures, 
Olig001 exhibits a 9-fold greater binding when compared with AAV8. This novel 
oligodendrocyte-preferring AAV vector exhibits characteristics that are a marked departure from 
previously described AAV serotypes.
INTRODUCTION
Adeno-associated virus (AAV) vectors occupy a prominent position in gene transfer studies, 
where in the central nervous system (CNS) AAV vectors support long-term, non-toxic gene 
expression for up to 8 years in non-human primates.1–3 These favorable properties have led 
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to a number of ongoing phase I clinical studies focused upon Parkinson’s disease, 
Alzheimer’s disease and Canavans, yet to date, no serious adverse effects have been 
attributed to the AAV vectors.4–6 The AAV serotypes most commonly used for CNS 
applications include AAV1, AAV2, AAV4, AAV5, AAV6, AAV8 and AAV9. Previously, 
AAV2 studies have dominated both preclinical and present clinical investigations, but recent 
discoveries of numerous distinct AAV serotypes have significantly expanded the 
transduction properties within the CNS.7–10 For example, AAV8 and AAV5 transduce a 
significantly greater area of the CNS in comparison with AAV2, whereas AAV9 can cross 
the blood–brain barrier and transduce both neurons and astrocytes after intravenous 
administration.7,10–11 Although these quantitative differences represent significant changes 
in the CNS transduction, very few differences exist in the cellular tropism, when a 
constitutive promoter drives gene expression. For example, after direct CNS infusion, almost 
all of the known AAV serotypes exhibit a dominant neuronal tropism, even across such 
diverse serotypes as AAV1, AAV2, AAV6, AAV8, AAV9, rh8, rh10, hu32 and hu37.7,12–14 
Some AAV capsids exhibit a weak tropism for oligodendrocytes when a cell-specific 
promoter drives expression (myelin basic protein). However, the overall transduction of 
oligodendrocytes is still low.15–16 Despite the fact that many of these serotypes utilize 
different methods of cellular entry and intracellular trafficking, all of these diverse serotypes 
exhibit a dominant neuronal tropism.7,10,12–13 The only exception is AAV4, which 
transduces ependymal cells, but not neurons, astrocytes, microglia or oligodendrocytes.8 
Similarly, this pervasive neuronal tropism also extends to numerous shuffled AAV capsid 
chimeras that were recovered in a previous study.17 Clearly, substantial neuronal tropism 
appears to be a central feature across widely diverse AAV capsid structures.
The AAV capsids have nine variable regions surrounded by conserved regions where the 
variable regions form loops and clusters on the exterior of the capsid.18–19 The unique 
topology of the AAV capsid confers cellular tropism by differential receptor binding. The 
first step of AAV transduction entails AAV binding to a primary receptor and co-receptor on 
the cell surface.18 After cellular uptake into endosomes, AAV subsequently escapes from the 
endosome/lysosome and traffics to the perinuclear compartment.20 These latter processes 
involve VP1- and VP2-specific portions of the capsid that contain acidification-responsive 
phospholipase domains and the nuclear localization signal.20 Upon nuclear entry, the AAV 
virion uncoats, followed by AAV genome second-strand synthesis and, finally, transgene 
expression.20 The present studies characterize a novel AAV vector generated from capsid 
shuffling and directed evolution that preferentially targets oligodendrocytes following 
intracranial injection into the striatum. Further, it shows increased extracellular binding to 
oligodendrocytes in vitro suggesting that the increased oligodendrocyte tropism is a result of 
external receptor interactions rather than downstream intracellular events.
RESULTS AND DISCUSSION
Identification of an oligodendrocyte-preferring AAV capsid
A shuffled AAV capsid library was created as described,17 using the following parent 
capsids as starting material: AAV1, AAV2, AAV2i8,21 AAV2.5,22 AAV6, AAV8, AAV9, 
AAV9.47,23 AAVrh10 and capsids recovered from unrelated ongoing shuffling projects. The 
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shuffled AAV capsid library was administered intravenously to a Sprague–Dawley rat 2 
weeks after unilateral striatal administration of 6-hydroxy-dopamine (6-OHDA), and 3 days 
later AAV clones were recovered by PCR from dissociated striatal cells. The model creates a 
unique selective pressure on AAV, because 6-OHDA causes dopamine containing nerve 
terminals to degenerate, which leads to oligodendrocyte precursor cell infiltration.24,25 
Surprisingly, 10 of 10 selected clones had highly similar, if not identical sequences. Even 
with a second round of capsid shuffling, library administration and clone selection, 12 out of 
12 clones had almost identical sequences, similar to the first round (Figure 1a). When the 
chimeric virus (named Olig001) was administered intravenously to unilateral 6-OHDA-
treated rats, 2 weeks later immunohistochemistry revealed only a few green fluorescent 
protein (GFP)-positive neurons in the ipsilateral striatum and a sparse number of 
oligodendrocyte-like cells (data not shown). In marked contrast, 2 weeks after a striatal 
infusion of the Olig001 clone into naïve rats, oligodendrocytes comprised the vast majority 
of the transduced cells, even though GFP expression was driven by the constitutive chicken 
beta actin promoter (CBh) promoter (Figure 1).26 The Olig001 capsid DNA sequence is 
shown in Figure 2, and a multiple protein alignment of Olig001 and its parental serotypes is 
shown in Figure 3. GFP-positive cells exhibited the typical oligodendrocyte morphology 
with clear labeling of myelin in the patch component of the striatal patch/matrix (Figure 1b). 
Furthermore, GFP-positive cells did not co-localize with glial fibrillary acidic protein, an 
astrocyte marker (Figure 1c), and < 5% of the GFP-positive cells co-localized with NeuN, a 
neuronal marker (Figure 1d). GFP-positive cells exhibit the typical morphology of striatal 
oligodendrocytes and co-localize with two oligodendrocyte markers, Olig2 (Figure 1e–g) 
and myelin basic protein (Figure 1h–j). Thus, almost all of the GFP-positive cells (> 95%) 
were oligodendrocytes with only a few neurons and no GFP-positive astrocytes or microglia.
These studies generated a novel chimeric AAV capsid variant with a preferential in vivo 
tropism for oligodendrocytes, a finding that represents a major departure from the normal 
neuronal tropism indicative of the parental AAV serotypes, except AAV4. AAV8 and AAV9 
exhibit a dominant neuronal tropism after direct injection into the rodent striatum9,13,16,27 as 
well as in other brain structures.12,28,29 Past studies have described the ability of AAV2 or 
AAV8 to transduce oligodendrocytes at a low efficiency, but these studies required the use of 
oligodendrocyte-specific promoters to prevent expression in neurons, the preferred cell type 
for these vectors.15,16 In contrast, using a ubiquitous promoter Olig001 has the ability to 
efficiently and preferentially transduce oligodendrocytes following intracranial 
administration. Thus, in the striatum Olig001 exhibits a preferred tropism for 
oligodendrocytes and low tropism for neurons, which is distinct from any previously 
reported AAV capsid.
Olig001 is detargeted from peripheral tissues
Given that the selection process involved intravenous administration of the capsid library, we 
sought to characterize the biodistribution of Olig001 in wild-type rodents compared with 
AAV8, the most represented AAV serotype in Olig001. Adult female C57Bl/6 mice received 
intravenous administration of equal amounts of either virus (5 × 1010 vg per mouse). Ten 
days later, organs were harvested, and the biodistribution was quantified by qPCR of the 
CBh-GFP transgene of Olig001-CBh-GFP (white bars) and AAV8-CBh-GFP (gray bars) 
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(Figure 4). The biodistribution of Olig001 was significantly reduced in all peripheral organs 
tested compared with AAV8, especially in the liver. The biodistribution of Olig001 indicates 
that it is not able to cross the blood–brain barrier, which was confirmed by a lack of GFP-
positive staining in the brain by immunohistochemistry (data not shown). The peripheral 
tissue biodistribution profile of Olig001 is reduced in comparison with AAV1, AAV5 and 
AAV6 also.30 Again, these data indicate that Olig001 has a highly divergent tropism from 
other AAV serotypes outside the CNS.
In vitro binding data
We performed an in vitro binding experiment using mixed glial cell cultures to better 
quantify the cell binding difference between Olig001 and AAV8, the most prominent 
parental serotype in Olig001. Mixed glial cell cultures were incubated with an equivalent 
amount of each virus, packaged with CBh-GFP transgene, for 1 h at 4 °C. This procedure 
allows vector binding to the cell surface, but prevents internalization.31 After 1 h, the cells 
were washed with phosphate-buffered saline (PBS) to remove any unbound vector, then the 
cells were collected and total DNA was isolated from the cells. The amount of vector bound 
to cells was quantified by qPCR for GFP and normalized to mouse genomic LaminB2 
(Figure 5a). Consistent with our in vivo results, Olig001 bound to the mixed glial cell 
population 9-fold more than AAV8. The proportion of oligodendrocytes in our mixed glial 
cell cultures were quantified by O4-positive staining of sister plates treated with AAV8 and 
Olig001 virus (Figure 5b). The AAV8-treated sister plate contained 89% O4-positive cells 
and the Olig001-treated sister plate contained 86% O4-positive cells indicating that the 
majority of the cells are oligodendrocytes and present in a similar percentage between the 
two conditions. Therefore, our in vitro data agrees with the observed in vivo tropism data of 
Olig001. These results indicate that in vitro Olig001 has a greater binding affinity for glial 
cell surface receptors than AAV8.
In total, our data describes a unique AAV vector with preferential oligodendrocyte tropism 
within the CNS and clear detargeting from peripheral tissues when intravenously injected. 
Thus, the Olig001 vector could be useful for in vivo and in vitro research applications 
requiring gene transfer to oligodendrocytes, which are typically refractory to efficient 
chemical transfection or vector-mediated transduction. Moreover, the ability to efficiently 
target oligodendrocytes in vivo could advance therapeutic strategies for demyelinating 
diseases such as Canavan disease or Krabbe disease.
MATERIALS AND METHODS
AAV capsid DNA shuffling and in vivo clone rescue
A shuffled AAV capsid was created as described17 using the following parent capsids as 
starting material: AAV1, AAV2, AAV2i8,21 AAV2.5,22 AAV6, AAV8, AAV9, AAV9.47,23 
AAVrh10 and capsids recovered from unrelated ongoing shuffling projects.32 The shuffled 
library was injected intravenously into rats that previously received a striatal 6-OHDA 
treatment. Three days later, the rats were killed and striatal cells were mechanically 
dissociated. DNA was recovered from neuron-enriched samples using the Qiagen DNeasy 
blood and tissue kit (Venlo, Netherlands) and subsequently concentrated by ethanol 
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precipitation. Intact capsid library sequences were recovered by PCR using a high-fidelity 
polymerase, Pfu Ultra II (Agilent, Santa Clara, CA, USA), with primers SwaICapUP 5′-
GCGAATGATTTAAATCAGGTATGGCTGC-3′ and P4ext 5′-
AAGCTCTAGACGGACACCAAAGTTCAACT-3′. A subsequent error-prone PCR step 
was employed to further diversify the library between rounds. Cloning and library 
amplification between selection rounds was carried out as previously described.17 A total of 
two rounds of selection were performed. Recovered clones after each round were subcloned 
into rAAV pXR2 backbones and SSV9 replication-competent backbones and sequenced.
AAV vector production
Recombinant AAVs were produced using a triple plasmid transfection method in HEK293 
cells, followed by iodixanol gradient centrifugation and ion-exchange chromatography, as 
previously described.33 All AAV vectors were packaged with a self-complementary genome 
with enhanced GFP under the control of a cytomegalovirus enhancer, miniature CBh chicken 
beta-actin hybrid and minute virus of mice intron.26 Peak fractions were dialyzed in PBS 
with 5% sorbitol, and NaCl added to a final concentration of 350 mM NaCl. Viral titers were 
obtained via qPCR (see below).
qPCR for biodistribution studies and viral titer
qPCR was used to determine viral titer and for biodistribution studies, as described.17 The 
quantity of GFP target sequence in each sample was normalized to the quantity of the 
LaminB2 locus, with data expressed as double-stranded copies of GFP per two double-
stranded copies of LaminB2. This approximates the copies of vector DNA per cell.
Animal procedures
All animals used in these studies were either male Sprague–Dawley rats (Charles River, 
Morrisville, NC, USA, 250–250 g) or adult female C57Bl/6 mice (Jackson Labs, Bar 
Harbor, ME, USA) that were maintained in a 12 h light–dark cycle and had free access to 
water and food. All care and procedures were in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals, and all procedures received prior 
approval by the University of North Carolina Institutional Animal Care and Use Committee.
6-hydroxy-dopamine treatment—Initially, rats (N = 2) were anesthetized with 50 mg 
kg−1 pentobarbital, intraperitoneal and placed into a stereotactic frame. Next, the rats 
received a unilateral infusion of 6-OHDA (2 µl, 20 µg µl−1) into the right striatum (0.5 mm 
anterior to bregma, 3.5 mm lateral, 5.5 mm vertical, according to the atlas of Paxinos and 
Watson).34 This treatment results in a significant reduction in striatal dopamine content 14 
days posttreatment.
AAV capsid library administration—The AAV capsid library was administered 14 days 
post-6-OHDA treatment. For each selection round, two rats were anesthetized initially with 
pentobarbital (50 mg kg−1 intraperitoneal) and subsequently received an intravenous tail 
vein injection of the AAV capsid library virus (100 µl, 6.7 × 1012 vg ml−1). Three days later, 
the rats were killed and the right striatum was dissected out. Subsequently, cells were 
mechanically dissociated as previously described17 for subsequent PCR clone rescue.
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Stereotactic AAV vector administration—As above, rats were anesthetized with 
pentobarbital and placed into a stereotactic frame. Olig001-CBh-GFP at a titer of 5.2 × 1012 
vg ml−1 was infused at a rate of 1 µl per 5 min (5.2 × 109 vg over 5 min) into the striatum 
(0.5 mm anterior to bregma, 3.5 mm lateral, 5.5 mm vertical), according to the rat brain atlas 
of Paxinos and Watson.34 The rats were killed for immunohistochemical evaluation 14 days 
post-vector infusion.
Immunohistochemistry—Fourteen days post-vector infusion, rats received an overdose 
of pentobarbital (100 mg kg−1, intraperitoneal) and subsequently were perfused 
transcardially with 100 ml of ice-cold 0.1 M PBS pH 7.4 (25 ml min−1), followed by 180 ml 
of ice-cold 4% paraformaldehyde-phosphate buffer (pH 7.4) (30 ml min−1). Each brain was 
post-fixed in 4% paraformaldehyde-phosphate buffer (pH 7.4) overnight at 4 °C. Fixed 
brains were sectioned coronally on a Leica (Wetzlar, Germany) vibratome (40-µm thick) and 
stored in ice-cold 0.1 M PBS pH 7.4 until further processing. For immunostaining, slides 
were washed three times for 5 min in 0.1 M PBS pH 7.4, then blocked in 10% goat serum 
and 0.1% Triton-X in 0.1 M PBS pH 7.4 for 30 min. Primary antibodies NeuN (1:500; 
Millipore, Bedford, MA, USA; MAB377), Olig2 (1:250; Millipore; AB9610) and glial 
fibrillary acidic protein (1:2000; Dako (Glostrup, Denmark); Z0334) were incubated in 5% 
goat serum and 0.05% Triton-X in 0.1 M PBS pH 7.4 at 4 °C with gentle agitation overnight. 
Sections were washed in 0.1 M PBS pH 7.4 and blocked again as described above. 
Secondary goat anti-mouse Alexa 594 (A11032) was used for detection of NeuN or goat 
anti-rabbit Alexa 594 (A11080) was used for detection of glial fibrillary acidic protein and 
Olig2 (both 1:500 in 5% goat serum and 0.5% Triton-X in 0.1 M PBS pH 7.4 with gentle 
agitation at 4 °C for 45 min). Sections were washed with 0.1 M PBS pH 7.4 three times for 5 
min each. Sections were floated, put on glass slides, and dried overnight at room 
temperature. Slides were then mounted with fluorescent mounting media and cover slipped. 
Confocal imaging was performed at the Michael Hooker Microscopy Core at UNC-Chapel 
Hill using a Leica Sp2 confocal. Slides were visualized using the oil 40× objective using 
sequential laser scanning to obtain z-stacks. Z-stacks were ~ 4 µm with 10–12 slices 0.36 µm 
thick per stack. Stacks were flattened in the Leica software and processed in Image J (NIH, 
Bethesda, MD, USA).
Biodistribution—Adult female C57Bl/6 mice (Jackson labs) were intravenously injected 
in the tail vein with 5 × 1010 vg (~2.5 × 1012 vg per kg body weight) in 200 µl PBS with 5% 
D-sorbitol. Ten days post injection organs were harvested. Total DNA from each organ was 
extracted with Qiagen DNeasy blood and tissue kit and total copies of GFP and mouse 
genomic LaminB2 were determined by qPCR. Data were compiled from five mice for AAV8 
and four mice for Olig001. The s.e. of the mean was calculated.
In vitro binding
Mixed glial cultures were prepared from C57BL/6J day 3 neonatal pups.35 Forebrains were 
minced, dissociated and washed prior to plating in T75 flasks. Cells were removed from the 
flasks and then replated into 35 mm tissue culture dishes with ~ 5 × 105 cells. At 95% 
confluency, Olig001 and AAV8 containing the CBh-GFP reporter genome were diluted and 
added separately, in quadruplicate, at a multiplicity of infection of 100 vg per cell and were 
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incubated at 4 °C with mixing every 10 min for 1 h. Plates were rinsed with ice-cold PBS 
three times, cells scraped from the plates, pelleted, and frozen at − 80 °C. A PBS only dish 
was also included as a mock sample. DNA was isolated from the samples using the Qiagen 
DNeasy blood and tissue kit. The amount of viral GFP and mouse genomic LaminB2 was 
determined by qPCR. Statistical analysis and graphing was done in Prism (GraphPad 
Software, La Jolla, CA, USA). Outliers were determined using the Grubbs test and 
subsequently removed. Statistical significance (P < 0.05) was determined using a one-tailed 
Mann–Whitney U-test. The fold change was determined using the average binding of each 
virus compared with average binding of AAV8. The errors bars on the fold difference graph 
were determined using percentages calculated from the binding data for each sample. To 
characterize the glial cell cultures, sister plates were provided glia media after the 1 h 
incubation at 4 °C with virus. The cultures were allowed to grow for 72 h at 37 °C. Cells 
were labeled with 10 µg ml−1 primary O4 antibody (MAB345, Millipore) followed by 5 µg 
ml−1 Alexa 594 (A21044, Invitrogen, Carlsbad, CA, USA) secondary antibody. Cells were 
fixed with 1% paraformaldehyde and stored at 4 °C until imaging. At least five independent 
fields were imaged on a Olympus IX71 inverted fluorescent microscope with cellSens Entry 
Software (Japan) and used for quantification of O4-positive cells in AAV8- and Olig001-
treated plates.
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Figure 1. 
Olig001 has an oligodendrocyte-preferring tropism. (a) Diagram of the cap gene from 
Olig001. Each color represents a different AAV parental serotype (blue = AAV2, purple = 
AAV8, red = AAV9, yellow = AAV1 and orange = AAV6) present in the input reaction of 
the library. The black vertical bars indicate point mutations. (b–j) Naïve rats were striatally 
infused with Olig001-CBh-GFP (5.2 × 109 vg over 5 min) and harvested 2 weeks later. (b) 
Confocal imaging shows Olig001 transduction of cells in the rat striatum that exhibit 
characteristics indicative of oligodendrocytes including the localization of GFP-positive 
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myelin in the patch of the striatal patch/matrix. (c) Confocal imaging reveals a lack of co-
localization of the GFP-positive cells with astrocytes labeled with glial fibrillary acidic 
protein (GFAP) (red) within the striatum. (d) Confocal imaging illustrates that the vast 
majority of Olig001-transduced cells within the striatum do not co-localize with a marker of 
neurons, NeuN (red). However, the arrow indicates a single GFP-/NeuN-positive cell. (e–g) 
Confocal imaging demonstrates that GFP-positive cells and Olig2 (red) co-localize. (h–j) 
Confocal imaging demonstrates that GFP-positive patches co-localize with MBP (myelin 
basic protein) patches within the striatum.
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Figure 2. 
DNA sequence of the cap gene of Olig001.
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Figure 3. 
Multiple protein alignment of Olig001 and parental serotypes (AAV1, 2, 6, 8 and 9) cap 
genes. Residues that are dark gray shaded are identical, light gray shaded are similar and 
white shaded are non-similar. The start sites for VP1, VP2 and VP3 are indicated. Regions 
that are required for transduction in VP1 and VP2 are indicated. Variable loops regions (VR) 
are indicated.
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Figure 4. 
Olig001 is detargeted from peripheral tissues compared with AAV8. Adult female C57Bl/6 
mice received an intravenous dose of 5 × 1010 vg (~2.5 × 1012 vg per kg body weight) of 
either Olig001-CBh-GFP (white bars; n = 4) or AAV8-CBh-GFP (gray bars; n = 5). Ten 
days later the organ distribution of GFP genome per diploid mouse genome (LaminB2) was 
determined by qPCR. Error bars indicate s.e. of the mean.
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Figure 5. 
In vitro binding analysis agrees with in vivo tropism. In vitro-mixed glial cell cultures were 
created by dissociating neonatal day 3 mouse brains. Plates containing ~ 5 × 105 cells were 
incubated with an multiplicity of infection of 100 vg per cell of AAV8-CBh-GFP, Olig001-
CBh-GFP or PBS only for 1 h at 4 °C to allow for vector binding, but not uptake. (a) The 
amount of vector bound to cells was quantified by qPCR for GFP and normalized to mouse 
genomic LaminB2. Error bars indicate s.e. of the mean, * indicates a significant difference 
of P < 0.03 and ** indicates a significant difference of P < 0.01 compared with AAV8. The 
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errors bars were determined using percentages calculated from the binding data for each 
sample. (b) Sister cultures treated with AAV8 and Olig001, as described above, were 
incubated at 37 °C for 72 h. After 72 h cells were stained for an oligodendrocyte marker, O4, 
to determine how enriched the mixed glial cultures were for oligodendrocytes. At least five 
fields were imaged in bright field and fluorescence for quantification; 89% of AAV8- and 
86% of Olig001-treated cells were O4-positive.
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